Search
ND7001
go.drugbank.com/drugs/DB05142ExperimentalND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. … It is a new type of antidepressant drug with anxiolytic activity.
Bismuth subcitrate potassium
go.drugbank.com/drugs/DB09275ApprovedInvestigationalA bismuth compound used for peptic ulcer and gastro-oesophageal reflux disease (GORD).
Pentolinium
go.drugbank.com/drugs/DB01090ApprovedPentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.
Farletuzumab
go.drugbank.com/drugs/DB05595InvestigationalFarletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.
Brentuximab
go.drugbank.com/drugs/DB05471InvestigationalBrentuximab (SGN-30) is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared … It is available commercially as the monoclonal antibody portion of the antibody-drug conjugate [brentuximab vedotin].
Pimagedine
go.drugbank.com/drugs/DB05383InvestigationalIt is beneficial in treating patients with diabetic nephropathy. … It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies.
Lexatumumab
go.drugbank.com/drugs/DB06599InvestigationalLexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).
IR501
go.drugbank.com/drugs/DB06464ExperimentalIR501 (Ravax) is a potential first-in-class vaccine for the treatment of Rheumatoid Arthritis. It specifically targets autoreactive T-cells, reducing their activity.
Guanabenz
go.drugbank.com/drugs/DB00629ApprovedWithdrawnGuanabenz is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.
AGS-004
go.drugbank.com/drugs/DB05742InvestigationalAGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden. … A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient.